Inactive Instrument
LYSOGENE Stock
Stocks
LYS
FR0013233475
Biotechnology & Medical Research
OTC Markets Traded
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 09/05/2014 | |
| Director of Finance/CFO | - | 01/11/2022 | |
Marie Trad
CTO | Chief Tech/Sci/R&D Officer | - | 01/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 54 | 22/05/2019 | |
Peter Lichtlen
BRD | Director/Board Member | 58 | 01/04/2018 |
Carole Deffez
BRD | Director/Board Member | - | 26/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 5.53M | |
| +0.51% | -5.71% | +124.34% | +99.75% | 4.44B | |
| -0.80% | -0.27% | +112.25% | +179.06% | 3.61B | |
| -1.94% | -12.41% | +62.71% | -33.33% | 2.19B | |
| -1.70% | +1.45% | -29.54% | -37.42% | 2.13B | |
| -0.85% | -6.49% | +181.78% | +222.94% | 1.88B | |
| +2.09% | -3.03% | +159.81% | -39.87% | 987M | |
| -7.09% | -1.50% | -13.10% | +15.16% | 875M | |
| +1.19% | -1.78% | -40.45% | -14.48% | 491M | |
| -4.01% | +7.57% | -1.41% | - | 468M | |
| Average | -1.23% | -0.59% | +61.82% | +48.98% | 1.9B | |
| Weighted average by Cap. | -0.86% | -1.24% | +87.78% | +79.62% |
Employees
22
